Prolexys Pharmaceuticals, Inc.

John M Peltier

Moritz Von Rechenberg

Paul B Robbins

Brent R Stockwell

John Jay Boniface

Robert Selliah

Longwu Qi

Raj Gopal Venkat

Sudhir R Sahasrabudhe

Justin Savage

Robert R Becklin

Cindy Lou Chepanoske

Keith Simmon

Eugene Y Zhen

Vladimir Kery

The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.

Quinoxaline derivatives as antitumor agents

The present invention provides a method for purifying a protein complex and the components comprising the complex from a cell, a cell or tissue lysate or a whole organism by employing a combined set of affinity tags of high affinity, specificity and ease of elution. The method involves using a protein or a peptide modified to contain one or more affinity tags separated by one or more specific protease cleavage sites to isolate any interacting proteins or fragments thereof. Specifically exemplified is a method employing a modified bait containing AviTag or GST and a removal tag of Hishexapeptide positioned proximal to the bait such that any excess bait can be efficiently removed from the purified complex yielding enriched interacting proteins prior to subjecting the complex for further identification of individual components. The identification of the proteins or fragments thereof contained in the protein complex will provide new targets for the identification of new pharmaceuticals and diagnostic tools.

Method for purification of a protein complex and identification of its components

Growing community of inventors

Jefferson, MD, United States of America

John M Peltier